Guest Editor(s)

• Stefano Bellentani, MD, PhD

  Independent Consultant Hepatologist and Gastroenterologist Studio Gastro Lugano/Chiasso and Ambulatorio Medico Locarno, Ticino, Switzerland; Fondazione Italiana Fegato (FIF) Trieste, Italy.

  Website | E-mail

Special Issue Introduction

Non-Alcoholic Liver Disease (NAFLD) is an emerging chronic liver disease correlated to insulin resistance and dysmetabolic disease worldwide. The global epidemiology is almost well-designed as far as concerning the prevalence but not for the incidence and the natural history. NAFLD/NASH (non-alcoholic steato-hepatitis) is the second indication for liver transplant in USA nowadays. We know that the liver-correlated cause of mortality of patients with NAFLD is only the third leading cause of death, the first cause is cardiovascular diseases and the second is colonic cancer in men and breast cancer in women.
The scientific community still does not have in his hands all the appropriate tools to make a correct non-invasive diagnosis to identify patients with NAFLD who can evolve in NASH or to understand who is going to progress more or less rapidly towards fibrosis/cirrhosis and/or hepatocellular carcinoma (HCC) or towards cardiovascular disease or cancer.
A lot of work must be still done both in the definition and classification of NAFLD and NASH and in identifying patients at risk to evolve towards a more aggressive form of liver disease or to die. Surveillance policy for population at risk is not yet applicable in the real practice. Finally, no effective treatments are still on the market even if more than 250 clinical trials on new drugs are ongoing worldwide.
In this special issue of Hepatoma Research, the real Global Epidemiology and Natural History, and new updated insights especially in the actual incidence and future trends of this new epidemic burden will be discussed by the major experts in this field.

Potential topics include, but are not limited to the following titles.
1. The global Prevalence of NAFLD and NASH
2. It is time for a New Definition of NAFLD/NASH?
3. The global Incidence of NAFLD/NASH and trend for the future
4. The "Juvenile NASH": fact or fiction?
5. The Natural History of NAFLD patients evolving to Cardiovascular Diseases (CVD)
6. The Natural History of NAFLD patients evolving to not-liver related Cancer
7. The Natural History of NAFLD patients evolving to end-stage liver diseases
8. The prevalence of Hepatocellular Carcinoma (HCC) in patients with NASH
9. The prevalence of HCC in patients with Diabetes or Obesity
10. The future trend of NAFLD/NASH: global burden epidemic or fake-news?
11. Future prospective for a better diagnosis and prognosis of NASH/NAFLD

Participants

1. Claudio Tiribelli & Pablo José Giraudi  Fondazione Italiana Fegato-ONLUS, Liver Research Center, Basovizza, Trieste, Italy.
2. Yoshio Sumida  Department of Gastroenterology, Aichi Medical University, Nagakute, Aichi, Japan.
3. Manuela Neuman  Department of Pharmacology & Toxicology, University of Toronto, Canada.
4. Carolin Lackner  Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University of Graz, Graz, Austria.
5. Christian Datz  Department of Internal Medicine, Oberndorf Hospital, Oberndorf, Austria.
6. Ramy Younes  Department of Medical Sciences, University of Turin, Gastroenterology Division of Città della Salute e della Scienza of Turin, University Hospital, Turin, Italy.
7. Giulia Besutti  Department of Imaging and Laboratory Medicine, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
8. Sven Francque  Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium.
9. Cynthia Ureta Checcllo  Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.
10. Antonio Ponzetto  Department of Medical Sciences, University of Torino, Torino, Italy.
11. Aurora Giannetti  Sezione di Gastroenterologia e Epatologia, PROMISE, University of Palermo, Palermo, Italy.
12. Ma Ai Thanda Han  Liver Diseases Branch, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, Maryland, USA.
13. Naim Alkhouri  Division of Gastroenterology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
14. Kaichun Wu  State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Shaanxi, China.
15. Andrea De Gottardi & Pietro Majno  Department for Biomedical Research, Hepatology, University of Bern, Switzerland; Department of Surgery, Regional Hospital of Lugano, Lugano, Switzerland.
16. Amedeo Lonardo  Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy.
17. Gianluca Svegliati-Baroni  Department of Gastroenterology, Polytechnic University of Marche, Ancona, Italy.
18. Mariana Verdelho Machado  Serviço de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Av. Prof. Egas Moniz, Lisbon, Portugal.
19. Avik Majumdar  AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia; Central Clinical School, The University of Sydney, Sydney, Australia.
20. Bubu Banini  Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
21. Alessandro Mantovani  Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
22. Andrea Dalbeni  Section of General Medicine, Hypertension and Liver Unit, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
23. Giulio Marchesini  Unit of Metabolic Diseases & Clinical Dietetics, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
24. Giulio Marchesini & Lucia Brodosi  Department of Medical and Surgical Sciences, "Alma Mater" University, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
25. Giovanni Targher  Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
26. Claudia Pinto Marques Souza de Oliveira  Department of Gastroenterology, University of Sao Paulo, School of Medicine, Sao Paulo, Brazil.
27. Cristiane A. Villela-Nogueira  Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
28. Jun Yong Park  Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
29. Takuya Seike  Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan.
30. Cosimo Giannini  Department of Paediatrics, University of Chieti, Chieti, Italy.
31. Loning Fu  Department of Pediatrics, Molecular and Cellular Biology, Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, USA.
32. Ferruccio Bonino & Maurizia Brunetto Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; IRCSS SDN, Naples, Italy; Fondazione Italiana Fegato, AREA Science Park, Campus Basovizza, Trieste, Italy.
33. Elena Maiolo Area of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
The list is arranged in no particular order and being updated.

Submission Deadline

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/HR/?IssueId=402
Submission Deadline: 31 Aug 2020
Contacts: Ada Zhong, Assistant Editor, editor_Ada@hrjournal.net